CCM
AKBA icon

Consonance Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Consonance Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,031,283
Closed -$95.5M – 28
2020
Q2 		$95.5M Sell
7,031,283
-90,000
-1% -$931K 5.72% 6
2020
Q1 		$54M Buy
+7,121,283
New +$55.4M 4.02% 9
2019
Q2 		– Sell
-1,430,579
Closed -$11.7M – 31
2019
Q1 		$11.7M Buy
+1,430,579
New +$9.82M 0.74% 22

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Consonance Capital Management's AKBA Position: Q3 2020 in Review

Consonance Capital Management sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 7,031,283 shares — an estimated $95.5M sold.

Consonance Capital Management first reported a position in AKBA in Q1 2019 and held it in 3 quarters. The position peaked at $95.5M in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Consonance Capital Management reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Consonance Capital Management sold 7,031,283 Akebia Therapeutics shares in Q3 2020, an estimated $95.5M.
  • Consonance Capital Management first reported a position in Akebia Therapeutics in Q1 2019 and held it in 3 quarters.
  • Consonance Capital Management's Akebia Therapeutics position peaked at $95.5M in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Consonance Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.